Seiichi Mori
Seiichi Mori
Genome Center, Japanese Foundation for Cancer Research
Verified email at jfcr.or.jp
Title
Cited by
Cited by
Year
Development of peripheral lymphoid organs and natural killer cells depends on the helix–loop–helix inhibitor Id2
Y Yokota, A Mansouri, S Mori, S Sugawara, S Adachi, SI Nishikawa, ...
Nature 397 (6721), 702-706, 1999
9001999
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
T Baba, PA Convery, N Matsumura, RS Whitaker, E Kondoh, T Perry, ...
Oncogene 28 (2), 209-218, 2009
4432009
A bistable Rb–E2F switch underlies the restriction point
G Yao, TJ Lee, S Mori, JR Nevins, L You
Nature cell biology 10 (4), 476-482, 2008
3602008
Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients
TZ Tan, QH Miow, Y Miki, T Noda, S Mori, RYJ Huang, JP Thiery
EMBO molecular medicine 6 (10), 1279-1293, 2014
3352014
Role of Id family proteins in growth control
Y Yokota, S Mori
Journal of cellular physiology 190 (1), 21-28, 2002
2862002
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor …
RYJ Huang, MK Wong, TZ Tan, KT Kuay, AHC Ng, VY Chung, YS Chu, ...
Cell death & disease 4 (11), e915-e915, 2013
2422013
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death
TC Hallstrom, S Mori, JR Nevins
Cancer cell 13 (1), 11-22, 2008
2382008
Anchorage-independent cell growth signature identifies tumors with metastatic potential
S Mori, JT Chang, ER Andrechek, N Matsumura, T Baba, G Yao, JW Kim, ...
Oncogene 28 (31), 2796-2805, 2009
2362009
The genomic analysis of lactic acidosis and acidosis response in human cancers
JLY Chen, JE Lucas, T Schroeder, S Mori, J Wu, J Nevins, M Dewhirst, ...
PLoS Genet 4 (12), e1000293, 2008
1682008
Lactation defect in mice lacking the helix–loop–helix inhibitor Id2
S Mori, SI Nishikawa, Y Yokota
The EMBO journal 19 (21), 5772-5781, 2000
1532000
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
TZ Tan, QH Miow, RYJ Huang, MK Wong, J Ye, JA Lau, MC Wu, ...
EMBO molecular medicine 5 (7), 1051-1066, 2013
1442013
A genomic strategy to elucidate modules of oncogenic pathway signaling networks
JT Chang, C Carvalho, S Mori, AH Bild, ML Gatza, Q Wang, JE Lucas, ...
Molecular cell 34 (1), 104-114, 2009
1292009
SIRT2 down‐regulation in HeLa can induce p53 accumulation via p38 MAPK activation‐dependent p300 decrease, eventually leading to apoptosis
Y Li, H Matsumori, Y Nakayama, M Osaki, H Kojima, A Kurimasa, H Ito, ...
Genes to Cells 16 (1), 34-45, 2011
1082011
Using a stem cell–based signature to guide therapeutic selection in cancer
I Shats, ML Gatza, JT Chang, S Mori, J Wang, J Rich, JR Nevins
Cancer research 71 (5), 1772-1780, 2011
1062011
A role for E2F6 in distinguishing G1/S-and G2/M-specific transcription
PH Giangrande, W Zhu, S Schlisio, X Sun, S Mori, S Gaubatz, JR Nevins
Genes & development 18 (23), 2941-2951, 2004
1032004
A novel snail-related transcription factor Smuc regulates basic helix–loop–helix transcription factor activities via specific E-box motifs
H Kataoka, T Murayama, M Yokode, S Mori, H Sano, H Ozaki, Y Yokota, ...
Nucleic acids research 28 (2), 626-633, 2000
1032000
FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway
M Asad, MK Wong, TZ Tan, M Choolani, J Low, S Mori, D Virshup, ...
Cell death & disease 5 (7), e1346-e1346, 2014
892014
Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer
QH Miow, TZ Tan, J Ye, JA Lau, T Yokomizo, JP Thiery, S Mori
Oncogene 34 (15), 1899-1907, 2015
882015
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer
N Matsumura, Z Huang, S Mori, T Baba, S Fujii, I Konishi, ES Iversen, ...
Genome research 21 (1), 74-82, 2011
882011
Utilization of pathway signatures to reveal distinct types of B lymphoma in the Eμ-myc model and human diffuse large B-cell lymphoma
S Mori, RE Rempel, JT Chang, G Yao, AS Lagoo, A Potti, A Bild, ...
Cancer research 68 (20), 8525-8534, 2008
712008
The system can't perform the operation now. Try again later.
Articles 1–20